Fig. 7: Upregulation of the immunotherapeutic ability of Monalizumab by PANC754 combination. | Cell Death & Disease

Fig. 7: Upregulation of the immunotherapeutic ability of Monalizumab by PANC754 combination.

From: M6A-METTL3-dependent nuclear PANC754/PSPC1/H3K4me1 repression complex regulate immune evasive LGALS7 signal to enhance immunotherapy against colorectal cancer

Fig. 7

A The flowchart of co-culture system of PANC754 and the immune checkpoint blockage (ICB) of NKG2A gene, Monalizumab (Created by Figdraw). B The Perforin content in the culture supernatant of co-culture system was detected by ELISA. PF, Perforin; CRC, HCT116 cells; Control, transfected with empty plasmids; PBMC, peripheral blood mononuclear cells; OE-PANC754, transfected with PANC754 overexpression plasmid. C The apoptosis rate of HCT116 cells was detected by FCM. *P < 0.05; **P < 0.01; ***P < 0.001; ns, no significance. D The LDH concentration in the culture supernatant detected by velocity method in the biochemical analyzer. E The LDH concentration in the culture supernatant detected by ELISA. Gzms-B, granzyme B. F E-cadherin protein level in HCT116 cells was determined by immunocytochemical (ICC) staining. G The positive rate of MMP9 protein in HCT116 cells was determined by ICC staining. H The mRNA level of LGALS7 gene in HCT116 cells was determined by qRT-PCR. ****P < 0.0001. Each experiment was repeated at least three times.

Back to article page